Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castration-Resistant Prostate Carcinoma”

1,517 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,517 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 23
Very early researchUnknownNCT02691169
What this trial is testing

Integrated 18F-labelled PSMA Project

Who this might be right for
Prostate Cancer
St. Joseph's Healthcare Hamilton 10
Testing effectiveness (Phase 2)Ended earlyNCT01093183
What this trial is testing

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer
University of Nebraska 25
Not applicableLooking for participantsNCT06600802
What this trial is testing

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Who this might be right for
Castration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)
Centre Jean Perrin 120
Not applicableStudy completedNCT03223727
What this trial is testing

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

Who this might be right for
Prostate Cancer MetastaticBone Metastases
The Netherlands Cancer Institute 100
Early research (Phase 1)Looking for participantsNCT07316686
What this trial is testing

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Instituto do Cancer do Estado de São Paulo 18
Early research (Phase 1)Study completedNCT03629756
What this trial is testing

Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Who this might be right for
Non-small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckBreast Cancer+9 more
Arcus Biosciences, Inc. 48
Early research (Phase 1)Looking for participantsNCT06062745
What this trial is testing

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Who this might be right for
Advanced Prostate CancerMetastatic Prostate CancerMetastatic Prostate Neuroendocrine Carcinoma
Brigham and Women's Hospital 30
Large-scale testing (Phase 3)Ended earlyNCT03850795
What this trial is testing

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer MetastaticCastration-resistant Prostate Cancer
Hinova Pharmaceuticals USA, Inc. 104
Testing effectiveness (Phase 2)Looking for participantsNCT05413850
What this trial is testing

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more
Blue Earth Therapeutics Ltd 82
Early research (Phase 1)Study completedNCT00868595
What this trial is testing

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Who this might be right for
Castrate Resistant Prostate Cancer (CRPC)
Bellicum Pharmaceuticals 18
Testing effectiveness (Phase 2)Study completedNCT02047253
What this trial is testing

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
University of Alabama at Birmingham 28
Early research (Phase 1)Looking for participantsNCT07621692
What this trial is testing

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
National Taiwan University Hospital 12
Post-approval studies (Phase 4)Study completedNCT02102646
What this trial is testing

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

Who this might be right for
Prostate CancerMetabolic SyndromeHypogonadism+1 more
Herlev Hospital 31
Testing effectiveness (Phase 2)UnknownNCT04486937
What this trial is testing

SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 90
Testing effectiveness (Phase 2)UnknownNCT02484339
What this trial is testing

Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)

Who this might be right for
Prostate Carcinoma
University Hospital Freiburg 274
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Testing effectiveness (Phase 2)Study completedNCT00450619
What this trial is testing

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Study completedNCT02125357
What this trial is testing

Sequencing Abiraterone and Enzalutamide in mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
British Columbia Cancer Agency 202
Large-scale testing (Phase 3)Study completedNCT03016312
What this trial is testing

Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Hoffmann-La Roche 759
Next Page